Zhaoke Ophthalmology secures NMPA approvals for key eye treatments

Zhaoke Ophthalmology Limited announced on November 24, 2025, that its Investigational New Drug (IND) application for PAN-90806 eye drop, targeting wet (neovascular) age-related macular degeneration (wAMD), was approved by China's National Medical Products Administration (NMPA) on November 18, 2025. PAN-90806 is an anti-VEGF agent designed as a novel small-molecule eye drop, aiming to offer a less invasive maintenance therapy for wAMD patients.

In a separate development, the company also secured marketing authorizations from the NMPA on November 19, 2025, for Epinastine HCl eye drop, intended for the treatment of allergic conjunctivitis. Epinastine HCl, a generic to Allergan's Elestat, functions with a dual mechanism as an anti-histamine and mast cell stabilizer, positioning it as a first-line therapy for allergic conjunctivitis in China.

The wAMD market in China, according to China Insights Consultancy, is projected to grow from $241.5m in 2019 to approximately $3.5bn by 2030, reflecting a compound annual growth rate (CAGR) of 27.5%. Zhaoke Ophthalmology cautions that there is no guarantee PAN-90806 will be successfully developed or commercialized.